文献速递哮喘呼吸道感染

度普利尤单抗对比奥马珠单抗治疗慢性鼻窦炎伴鼻息肉合并哮喘(EVEREST):多中心随机双盲头对头4期试验

Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
PubMed 文献 · Lancet Respir Med · 2025-09-28

EVEREST是首个呼吸生物制剂头对头试验,在17国100中心随机360例重度慢性鼻窦炎伴鼻息肉(CRSwNP)合并哮喘患者,比较度普利尤单抗与奥马珠单抗24周疗效与安全性。度普利尤单抗在鼻息肉评分和嗅觉识别测试等所有主要和次要终点均显著优于奥马珠单抗,安全性事件谱与已知一致。

要点

  • 两组治疗中出现的不良事件发生率分别为64%和67%,最常见为上呼吸道感染、头痛和咳嗽。

核心结论

  • 在重度CRSwNP合并哮喘患者中,度普利尤单抗在24周时对所有主要和次要疗效终点均显著优于奥马珠单抗。
  • 度普利尤单抗与奥马珠单抗的安全性特征与已知一致,研究期间无死亡病例。

研究设计与样本

  • EVEREST为国际多中心、随机、双盲、头对头4期试验,在17个国家100家医院或临床中心开展。
  • 共筛查819例,随机360例(度普利尤单抗组181例,奥马珠单抗组179例),纳入18岁及以上重度未控制CRSwNP合并医生诊断哮喘患者。
  • 患者1:1随机接受皮下度普利尤单抗300 mg每2周一次或奥马珠单抗按体重和IgE分层每2周或每4周一次,疗程24周,背景使用糠酸莫米松鼻喷雾剂。
  • 主要终点为24周时内镜下鼻息肉评分和UPSIT嗅觉识别测试较基线的变化,疗效按意向治疗人群分析,安全性按至少接受一剂研究药物者分析。

主要发现

  • 度普利尤单抗组179例中115例(64%)报告治疗中出现的不良事件,奥马珠单抗组173例中116例(67%)报告。
  • 最常见治疗中出现的不良事件包括鼻咽炎、意外过量、头痛、上呼吸道感染和咳嗽。
  • 研究期间无死亡病例。

关键数值与推荐

  • 入组要求鼻息肉评分≥5分(且每侧鼻孔≥2分),筛查前鼻塞和嗅觉丧失症状持续至少8周,且合并医生诊断哮喘。
  • 筛查排除标准包括:167例不符合鼻息肉评分≥5分或持续鼻塞和嗅觉丧失症状,114例不符合支气管舒张前FEV1≤85%预计值,99例不符合奥马珠单抗药物剂量资格。
  • 度普利尤单抗给药方案为皮下300 mg每2周一次;奥马珠单抗按体重和IgE分层每2周或每4周一次。

临床怎么用

  • 对于重度CRSwNP合并哮喘且适合生物制剂治疗的患者,度普利尤单抗在改善鼻息肉和嗅觉方面可能优于奥马珠单抗。
  • 度普利尤单抗和奥马珠单抗的安全性谱与已知一致,选择生物制剂时可结合表型特征进行靶向治疗。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation. The biologics dupilumab and omalizumab, which target drivers and mediators of type 2 inflammation (interleukin [IL]-4/IL-13 signaling and immunoglobulin E [IgE], respectively), are efficacious in treating CRSwNP but direct comparisons are few. In EVEREST (EValuating trEatment RESponses of dupilumab versus omalizumab), the first head-to-head trial in respiratory biologics, we aimed to compare the efficacy and safety of dupilumab and omalizumab in patients with severe CRSwNP who had mild, moderate, or severe asthma. METHODS: EVEREST was an international, randomised, double-blind, phase 4 trial, conducted at 100 hospitals or clinical centres in 17 countries. Sites were selected with otolaryngology, pneumologist, allergist, and immunologist practices; needed to have previously conducted double-blind studies; and were required have nasal endoscopy and electrocardiogram machines. Eligible patients aged 18 years or older with severe uncontrolled CRSwNP (with a nasal polyp score of 5 or more [and ≥2 for each nostril]), symptoms of nasal congestion and loss of smell for at least 8 weeks before screening, and physician-diagnosed asthma. Patients were randomly assigned (1:1) to subcutaneous dupilumab 300 mg every 2 weeks or omalizumab weight-tiered and IgE-tiered dosing every 2 weeks or 4 weeks for 24 weeks, with background mometasone furoate nasal spray. Patients and investigators were masked to the study drugs. Primary endpoints were change from baseline in endoscopic nasal polyp score and University of Pennsylvania Smell Identification Test (UPSIT) at 24 weeks. Efficacy was assessed in the intention-to-treat population and safety was assessed in patients who received at least one dose of study medication. The trial was registered at ClinicalTrials.gov, NCT04998604. FINDINGS: Between Sept 27, 2021, and Dec 27, 2024, 819 individuals were screened for study inclusion, 459 were excluded (most common screen failures were: 167 did not meet nasal polyp score ≥5 or did not have ongoing symptoms of nasal congestion and loss of smell, 114 did not meet pre-bronchodilator FEV1 ≤85% predicted normal, and 99 did not meet eligibility as per omalizumab drug-dosing), and 360 participants were randomly assigned (181 assigned to the dupilumab group and 179 assigned to the omalizumab group). Of the 360 participants, 198 (55%) participants were male, 162 (45%) were female, and the mean age of the total population sample was 52 years (SD 13·1). Improvements were significantly greater with dupilumab than omalizumab for all primary and secondary efficacy endpoints at week 24. Least squares mean differences in change from baseline dupilumab over omalizumab were: nasal polyp score -1·60 (95% CI -1·96 to -1·25; p<0·0001) and UPSIT 8·0 (6·3 to 9·7; p<0·0001). 115 (64%) of 179 participants in the dupilumab group and 116 (67%) of 173 participants in the omalizumab group reported treatment-emergent adverse events, the most common of which were nasopharyngitis, accidental overdose, headache, upper respiratory tract infection, and cough. There were no deaths in the study. INTERPRETATION: Dupilumab was superior to omalizumab in patients with severe CRSwNP and coexisting asthma. These findings support the efficacy of dupilumab in patients with type 2 respiratory diseases versus an active biologic comparator, the known safety profiles of dupilumab and omalizumab, and could enable better treatment targeting for patients with CRSwNP and asthma in clinical practice. FUNDING: Sanofi and Regeneron Pharmaceuticals.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. De Corso E, Canonica GW, Heffler E, et al. Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. Lancet Respir Med. 2025. PMID: 41033334. doi:10.1016/S2213-2600(25)00287-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。